Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
48.7 HKD +0.52% Intraday chart for Akeso, Inc. +10.93% +4.96%
Apr. 24 Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
Apr. 24 National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 25,172 22,635 31,941 39,033 39,033 -
Enterprise Value (EV) 1 22,680 20,843 31,716 35,470 40,551 38,983
P/E ratio -19.4 x -21 x -26.7 x 17.4 x -90.6 x 149 x
Yield - - - - - -
Capitalization / Revenue - 100 x 38.1 x 7.84 x 14.6 x 9.2 x
EV / Revenue - 92.4 x 37.9 x 7.84 x 15.1 x 9.18 x
EV / EBITDA -17.6 x -16 x -25.9 x 16.6 x -160 x 63.3 x
EV / FCF -19.3 x -12.1 x -15.5 x 31.6 x -68.1 x 321 x
FCF Yield -5.17% -8.24% -6.44% 3.16% -1.47% 0.31%
Price to Book 6.31 x 7.16 x 11.9 x 7.53 x 8.38 x 7.66 x
Nbr of stocks (in thousands) 787,057 817,057 841,057 865,857 865,857 -
Reference price 2 31.98 27.70 37.98 45.08 45.08 45.08
Announcement Date 3/31/21 3/30/22 3/15/23 3/18/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 - 225.6 837.7 4,526 2,679 4,245
EBITDA 1 -1,290 -1,302 -1,225 2,242 -252.9 615.4
EBIT 1 -1,313 -1,351 -1,331 2,049 -410.9 370.6
Operating Margin - -598.89% -158.92% 45.26% -15.34% 8.73%
Earnings before Tax (EBT) 1 -1,321 -1,258 -1,422 1,943 -450.3 287.9
Net income 1 -1,177 -1,075 -1,168 2,028 -405.7 247.4
Net margin - -476.42% -139.48% 44.81% -15.14% 5.83%
EPS 2 -1.650 -1.320 -1.420 2.420 -0.4974 0.3020
Free Cash Flow 1 -1,173 -1,717 -2,043 1,180 -595.6 121.6
FCF margin - -761.15% -243.88% 24.5% -22.23% 2.86%
FCF Conversion (EBITDA) - - - 52.62% - 19.76%
FCF Conversion (Net income) - - - 62.46% - 49.14%
Dividend per Share 2 - - - - - -
Announcement Date 3/31/21 3/30/22 3/15/23 3/18/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2
Net sales 1 - 97.03 - 674.5 3,677 849.4
EBITDA - - - - - -
EBIT - - - - 2,482 -433.9
Operating Margin - - - - 67.51% -51.09%
Earnings before Tax (EBT) 1 - -812 - -730.3 2,490 -547
Net income 1 -424.9 - -630.4 -538 2,525 -496.7
Net margin - - - -79.75% 68.67% -58.48%
EPS -0.5200 - -0.7700 - - -
Dividend per Share - - - - - -
Announcement Date 9/23/21 3/30/22 8/23/22 3/15/23 8/29/23 3/18/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - 1,518 -
Net Cash position 1 2,492 1,792 225 1,715 - 49.9
Leverage (Debt/EBITDA) - - - - -6.004 x -
Free Cash Flow 1 -1,173 -1,717 -2,043 1,180 -596 122
ROE (net income / shareholders' equity) -74% -33.9% -40.3% 55.4% -7.17% 5.4%
ROA (Net income/ Total Assets) -42.6% -24.8% -22.7% 27.6% -3.44% 5.25%
Assets 1 2,765 4,331 5,151 7,339 11,780 4,713
Book Value Per Share 2 5.060 3.870 3.200 5.600 5.380 5.880
Cash Flow per Share 2 -0.9800 -1.230 -1.500 2.950 -0.1000 0.4100
Capex 1 556 716 802 393 336 297
Capex / Sales - 317.39% 95.8% 8.16% 12.55% 7%
Announcement Date 3/31/21 3/30/22 3/15/23 3/18/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Akeso, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.08 CNY
Average target price
55.44 CNY
Spread / Average Target
+22.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AKESO, INC. Stock Akeso, Inc.
+4.96% 5.39B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. Financials Akeso, Inc.